Ivermectin was developed as an antiparasitic medication (from the soil-dwelling bacterium Streptomyces avermitilis), targeting specific ion channels that parasites rely on. Its effectiveness and safety profile made it one of the most widely used drugs in the world for parasitic disease control (later leading to a 2015 Nobel Prize due to its impact on global health). But as with many medications, its biological activity did not stop there.

Beyond its antiparasitic action, ivermectin has demonstrated anti-inflammatory properties: It has been shown to influence cytokine signaling and immune pathways involved in chronic inflammation. These effects help explain its usefulness in inflammatory skin conditions and ongoing research into inflammatory diseases such as arthritis.

Topical ivermectin is already an established treatment for rosacea, where it reduces inflammation and targets Demodex mites. This is a clear example of repurposing moving from observation to accepted clinical use.

Perhaps the most compelling area of ivermectin research lies in oncology. A growing body of preclinical studies has shown that ivermectin can interfere with metabolic processes that cancer cells depend on for survival.

Specifically, studies* have demonstrated that ivermectin can: Disrupt mitochondrial respiration: This means interfering with how cells use oxygen to make energy inside their “power plants” (the mitochondria), making it harder for fast-growing cells to survive.Interfere with glucose transport: This refers to blocking or slowing how cells take in sugar from the bloodstream, limiting the fuel they rely on to grow and divide.Reduce ATP (energy) production: ATP is the cell’s main energy currency; reducing ATP production leaves cells with less energy to carry out vital functions.Alter cellular redox balance: This means upsetting the balance between harmful oxidative molecules and the cell’s ability to neutralize them, which can push stressed cells toward damage or death. Cancer cells rely heavily on altered energy metabolism to sustain rapid growth and resist cell death. By disrupting these pathways, ivermectin has shown* anticancer and anti-inflammatory effects in laboratory, animal models, and in tens of thousands of humans globally.

Repurposing is a strategy
Drug repurposing does not replace rigorous science; it focuses it. Ivermectin belongs in this conversation not just because it is a powerful cure for many illnesses including cancer, but because it exemplifies a recurring pattern in medicine: molecules often do far more than we initially recognize. The question remains, who will invest millions of dollars in official trials to bring ivermectin to market, when a medication cannot be patented?